Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results.

@article{Czito2006IncreasedTW,
  title={Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results.},
  author={Brian Gary Czito and Christopher G Willett and Johanna C. Bendell and Michael Andew Morse and Douglas S. Tyler and Nishan H Fernando and Christopher R. Mantyh and Gerard C. Blobe and Wanda Honeycutt and Daohai Yu and Bryan M. Clary and Theodore N. Pappas and Kirk A. Ludwig and Herbert I. Hurwitz},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 4},
  pages={656-62}
}
PURPOSE Overexpression of epidermal growth factor receptor (EGFR) has been associated with aggressive tumor phenotypes, chemotherapy, and radiation resistance, as well as poor survival in preclinical and clinical models. The EGFR inhibitor gefitinib potentiates chemotherapy and radiation tumor cytotoxicity in preclinical models, including pancreatic and colorectal cancer. We initiated two phase I trials assessing the combination of gefitinib, capecitabine, and radiation in patients with… CONTINUE READING
49 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 49 extracted citations

Similar Papers

Loading similar papers…